Page last updated: 2024-08-23

etoposide and AL Amyloidosis

etoposide has been researched along with AL Amyloidosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Iwadate, D; Kawada, M; Ohashi, K; Sawa, N; Sekine, A; Sumida, K; Suwabe, T; Takaichi, K; Ubara, Y; Wake, A; Yamanouchi, M; Yuasa, M	1

Other Studies

1 other study(ies) available for etoposide and AL Amyloidosis

Article	Year
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency. Internal medicine (Tokyo, Japan), 2018, Mar-01, Volume: 57, Issue:5 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Biopsy; Combined Modality Therapy; Doxorubicin; Etoposide; Factor X Deficiency; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Remission Induction; Transplantation, Autologous	2018

Article

Year

The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.

Internal medicine (Tokyo, Japan), 2018, Mar-01, Volume: 57, Issue:5

Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Biopsy; Combined Modality Therapy; Doxorubicin; Etoposide; Factor X Deficiency; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Remission Induction; Transplantation, Autologous

2018